NASDAQ:EDIT Editas Medicine Q3 2026 Earnings Date & Estimates $2.44 -0.31 (-11.27%) Closing price 04:00 PM EasternExtended Trading$2.55 +0.11 (+4.47%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Editas Medicine is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for November 3, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeBefore Market OpensConference Call DateNovember 3, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Editas Medicine in Q3 2026Editas Medicine is expected to post earnings of -$0.21 per share on revenue of $4.54 million. In the same quarter a year earlier Editas Medicine reported -$0.28 per share on revenue of $7.54 million. Editas Medicine last reported on August 5, 2026, posting -$0.15 per share and beating the -$0.2705 consensus estimate. Editas Medicine has beaten the consensus EPS estimate in 5 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.21Expected Revenue$4.54 millionPrior-Year EPS-$0.28Prior-Year Revenue$7.54 millionExpected Revenue Growth-39.9%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.15 (Beat by +$0.1205)Last Quarter Revenue$11.89 millionEPS Beat Rate5 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Editas Medicine Q3 2026 Earnings FAQ When does Editas Medicine report Q3 2026 earnings? Editas Medicine (NASDAQ:EDIT) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Editas Medicine's Q3 2026 earnings call? Editas Medicine's Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Editas Medicine? Analysts expect Editas Medicine to post earnings of -$0.21 per share for Q3 2026. How much revenue is Editas Medicine expected to report? The consensus revenue estimate for Editas Medicine is $4.54 million for Q3 2026. Editas Medicine Earnings HeadlinesEditas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic ShiftOctober 12 at 1:53 PM | seekingalpha.comEditas Medicine (NASDAQ: EDIT) clears EDIT-401 for first-in-human trial in AustraliaOctober 11 at 6:03 AM | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)EDIT Set to Begin First-in-Human Study in HypercholesterolemiaOctober 9, 2026 | finance.yahoo.comEditas Medicine Receives Approval To Initiate Phase 1/2 Strive Clinical Trial Of EDIT-401 In Patients With Heterozygous Familial Hypercholesterolemia In AustraliaOctober 9, 2026 | marketscreener.comMWells Fargo Upgrades Editas Medicine to Overweight From Equal Weight, $6 Price TargetOctober 8, 2026 | finance.yahoo.comSee More Editas Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Editas Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Editas Medicine and other key companies, straight to your email. Email Address About Editas MedicineEditas Medicine (NASDAQ:EDIT) is a biotechnology company focused on developing genomic medicines that use CRISPR-based gene-editing technologies to treat diseases caused by genetic abnormalities. The company’s research programs are designed to modify or correct disease-associated genes in patients’ cells, with the goal of developing potentially durable treatments. Its lead investigational program is reni-cel, formerly known as EDIT-301, an ex vivo CRISPR gene-editing therapy being studied for sickle cell disease and transfusion-dependent beta thalassemia. Editas has also pursued additional programs involving both ex vivo and in vivo gene editing, including potential treatments for genetic diseases affecting the blood and eyes. These therapies remain investigational and are subject to clinical and regulatory evaluation. Founded in 2013 and headquartered in Cambridge, Massachusetts, Editas Medicine conducts research and clinical development activities intended to serve patients internationally. The company was established by researchers and biotechnology industry professionals, including prominent scientists associated with the development of CRISPR gene-editing technology. Its business is centered on advancing proprietary gene-editing platforms and translating them into medicines for serious diseases with limited treatment options.View Editas Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
